Product Pipeline
Asubio has an active portfolio of investigational compounds in development in the United States. Following is an overview of new drug candidates, their target indications and phase of clinical development.
| Entity | Phase of Development |
Indication | Status |
SUN11031 |
II | Cachexia | Available for Licensing |
SUN13834 |
II | Atopic Dermatitis | Available for Licensing |
SUN13837 |
II | Acute Spinal Cord Injury |
Clinical Development |
SUN11031
SUN11031 is a peptide hormone currently under Phase II investigation for the treatment of cachexia. Cachexia is the accelerated loss of tissue, primarily skeletal muscle, in the context of a chronic inflammatory response to many chronic or end-stage diseases. Clinically cachexia is characterized by weakness and a noticeable and progressive loss of body weight, fat, and muscle, and is a condition distinct from starvation. The largest cachexia patient populations are found in patients with COPD, chronic heart failure (CHF) and cancer. Similar changes have also been observed in the elderly. In COPD, CHF and cancer, 15% or more of patients suffer from cachexia associated with their condition. These patients experience both increased morbidity and mortality due to their cachexia, and unfortunately, few treatment options exist that both increase muscle mass and improve functional performance. SUN11031 has multiple activities that are expected to be beneficial in the treatment of cachexia.
Back to Top
SUN13834
SUN13834 is a chymase inhibitor currently under Phase II investigation for the treatment of atopic dermatitis (AD), commonly known as eczema. AD is a chronic inflammatory disease of the skin characterized by dry, red, extremely itchy areas of inflammation, most commonly on the face, inside the elbows, behind the knees, and on the hands and feet, that may cover over 20 to 30% of the body. AD is a very common disease in
children with prevalence estimates ranging from 10 to 20%. Approximately 20 million Americans have symptoms of AD. Although AD may occur at any
age, it most often begins in infancy and childhood.
Chymase is a chymotrypsin-like serine protease exclusively stored in secretory granules of mast cells and is thought to participate in
allergic inflammatory diseases. Preclinical models have suggested that inhibition of chymase with SUN13834 may reduce the inflammation and
pruritus associated with atopic dermatitis.
Back to Top
SUN13837
SUN13837 is a novel small molecule under development as a treatment for Acute Spinal Cord Injury (ASCI). SUN13837 exerts various biological activities similar to those of basic fibroblast growth factor (bFGF) through modulation of the signal transduction pathway of the fibroblast growth factor receptor (FGFR). SUN13837 exerts its bFGF-mimicking actions through the phosphorylation of tyrosine residues in the FGFR signaling cascade. However, it does not stimulate the proliferative actions which also characterize bFGF.
SUN13837 has shown neuroprotective and axonal outgrowth properties which could reduce neuronal damage and improve recovery following ASCI. SUN13837 has high aqueous and lipid solubility, making it more likely to cross biological membranes than a peptide such as bFGF. In animal models of ASCI, significant and remarkable functional recovery has been observed after treatment with SUN13837. These nonclinical study results in ASCI indicate that SUN13837 is a promising candidate for practical therapeutic use as an agent to stimulate axonal outgrowth as well as a neuroprotective agent.
Back to Top